Figure 1 A Case Series of Discordant Laboratory Results with Statewide Rapid HIV Testing in New Jersey Eugene G Martin, PhD 1, Gratian Salaru, MD 1, Sindy.

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
Post Marketing Surveillance of Oraquick Rapid HIV Testing Laura Wesolowski, PhD Gale R Burstein, MD, MPH Julia Zhu, MS Steven Ethridge, MT Division of.
Unit 6 Diagnosis & Follow-up of HIV Infection
Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers.
Evaluation of a Three Rapid Test Algorithm for the Diagnosis of HIV Infection at Point-of-Care Rapid Testing Facilities: Strategy 4 Data Needs. R. Boromisa.
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
Comparative Performance of Dual 3rd Generation Immunoassays as a Potential Laboratory-Based HIV-1/2 Testing Strategy. B. Bennett, S. Fordan, O. David,
Implementing Rapid HIV Testing in Non-traditional Sites Gratian Salaru, M.D. 1, Evan M. Cadoff, M.D. 1, Sindy M. Paul, M.D. 2, Vivian H. Shih, BA 1, Dolores.
Resolution of Discordant Confirmatory Results on POC Reactive Rapid Tests: Florida’s Pilot Project HIV Diagnostics: New Developments and Challenges Feb.
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
Integrating Rapid HIV Testing in Emergency Care Improves HIV Detection Evan M. Cadoff, MD Robert Wood Johnson Medical School New Brunswick, NJ
Abstract Background: Directed by the Department of Pathology and Laboratory Medicine at Robert Wood Johnson Medical School (RWJMS), and funded by New Jersey.
Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.
Can Sequentially Reactive EIA’s Replace HIV-1 Western Blot Testing? Robert A. Myers Ph.D.
12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.
CDC HIV Diagnostics Conference December 5-7, 2007 Sensitivity of OraQuick and Early Generation Enzyme Immunoassay (EIA) within a Pooled HIV Nucleic Acid.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,
HIV-1/HIV-2 COMBINATION SCREENING AND OUTCOMES OF FOLLOW UP William R. Oleszko, Ph.D. Associate Director, Public Health Laboratory Department of Health.
Can a second rapid HIV test discriminate false positives as effectively as a Western Blot? The NJ Experience Evan M. Cadoff, MD Robert Wood Johnson Medical.
Counseling Message: Both rapid tests we ran today were preliminary positive. It is likely that you have HIV. We always want to make absolutely sure, though,
METHODS  Based on initial OraQuick Post-Marketing Survey, the CDC made the recommendation that a discordant result should be followed-up by antibody testing.
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
HIV Testing CDC power point edited by M. Myers
APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005.
Screening for Acute HIV-1 Infection at NYC DOHMH Public Health Laboratory William R. Oleszko, Ph.D. Associate Director, Public Health Laboratory Department.
Incorporation of the Aptima® HIV-1 RNA Assay into Serodiagnostic and Rapid Test Confirmation Testing Algorithms to Resolve Discordant Serological Results.
HIV Testing Quality Assurance and Quality Control
Evaluation of a Proposed Testing Strategy for Laboratory-based Testing Using an HIV-1/2 Discriminatory Assay for HIV: Strategy 5 Data Needs. R. Boromisa,
Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.
Limitations of HIV Antibody Testing in a Population with High Incidence of HIV Infection Joanne Stekler 1,2, Paul D. Swenson 1,2, Robert W. Coombs 1, Joan.
HIV/AIDS is preventable and treatable, but is incurable.
HIV Diagnosis Jose-Luis Burgos, MD, AAHIVM Prevenmed-UCSD International Heath & Cross Cultural Medicine.
Integration of Rapid HIV Testing in Sexually Transmitted Disease Clinics In New Jersey Sindy M. Paul 1, Evan M. Cadoff 2, Eugene G. Martin 2, Maureen Wolski.
In the Footsteps of the WHO HIV Rapid Testing in the US Eugene G. Martin, Ph.D. Robert Wood Johnson Medical School New Brunswick, NJ CZECHOSLOVAK SOCIETY.
RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.
Development of a detuned oral assay for recent HIV infection F. Priddy 1, P. Phelan 1, P. Tambe 1,2, C. del Rio 1 1 Emory University School of Medicine,
Reducing the Delay: Can a Rapid HIV Test Discriminate False Positives as Effectively as a Western Blot – the NJ Experience Eugene G. Martin, Ph.D. *, Gratian.
ORAQUICK RAPID HIV TEST Medical Center of Louisiana Cynthia Eicher, MHS MT(ASCP)SBB Denise Friloux, RN, BSN, CIC.
Overview of Hepatitis B, C, and D Epidemiology in Eastern Europe and the Newly Independent States Michael O. Favorov MD, Ph.D., D.Sc. CDC Central Asia.
Results In New Jersey, the ability of satellite sites to start rapid testing is limited by the licensure process. In order to optimize the expansion of.
ABSTRACT Background: The New Jersey Department of Health and Senior Services, Division of HIV/AIDS Services (NJDHSS, DHAS)) introduced rapid HIV testing.
Rapid HIV Testing at Federally Qualified Health Care Centers in New Jersey Sindy M. Paul, M.D., M.P.H. 1, Eugene Martin, Ph.D. 2 Evan Cadoff, M.D. 2, Maureen.
Robert Wood Johnson Medical School Point of Care Testing Program Eugene G. Martin, Ph.D. Evan M. Cadoff, M.D., BLD Associate Professors of Pathology and.
HIV diagnosis (general) ImmunoassaysNAT (PCR)
In the Footsteps of the WHO – Rapid HIV Testing in America Eugene Martin, Ph.D. *, Gratian Salaru, M.D. *, Sindy M. Paul, M.D., M.P.H.**, Evan Cadoff,
Conclusions Our quality assurance system and databases allowed us to quickly evaluate our test results in response to reports of increased numbers of false.
E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
HIV Testing and Diagnosis of Emergency Department Patients New Jersey, Charlotte Sadashige, MSS * ; Sindy Paul, MD, MPH * ; Eugene Martin, PhD.
Update Rapid HIV Test Approval Requirements and Standards BPAC September 15, 2000 Kimber Poffenberger, Ph.D.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,
HIV/AIDS is preventable and treatable, but is incurable.
Statewide Implementation of a Rapid Testing Algorithm - New Jersey - Eugene Martin, Ph.D. UMDNJ – Robert Wood Johnson Medical School NHPC Annual Meeting.
ABSTRACT Purpose: Point-of-care rapid HIV testing is a new way to diagnose HIV disease. The New Jersey Department of Health and Senior Services Division.
 YEOH HUI SHIH –INTRODUCTION TO HIV  RAJAMANI- ELISA  TIEN WEI PING – WESTERN BLOTTING  YEO HUI YUN –OVERVIEW & CONCLUSION.
If the serum specimen fails to confirm, the frozen white top tube is collected by staff from NJ HIV and sent frozen overnight to ARUP laboratories (Salt.
 Direct  Indirect  Direct: -Microscopy -Culture -Antigen -Nucleic acid  Indirect: -Specific antibody (Serology)
CONCLUSIONS New Jersey’s Emergency Department HIV testing sites report higher seroprevalence than non-ED testing sites. Since University Hospital began.
Update Rapid HIV Testing in NJ
California Clinical Laboratory Association
In the Footsteps of the WHO – Rapid HIV Testing in America
San Francisco Department of Public Health
Annual HIV Coordinator’s Meeting 2011
INTEGRATING HIV AND HCV TESTING.
Recreational Vehicles with “laboratory” conversion.
A CASE SERIES OF DISCORDANT LABORATORY RESULTS WITH RAPID HIV TESTING
NJHIV's Rapid Testing Program Keeps False Positives in Check
Presentation transcript:

Figure 1 A Case Series of Discordant Laboratory Results with Statewide Rapid HIV Testing in New Jersey Eugene G Martin, PhD 1, Gratian Salaru, MD 1, Sindy M Paul, MD, MPH 2, Rose Marie Martin, MPH 2, Maureen Wolski,BA 2, Linda Berezny, BSN 2, Evan M Cadoff 1, MD 1 UMDNJ – Robert Wood Johnson Medical School and 2 New Jersey Department of Health and Senior Services Abstract Background: A statewide case series of patients with discordant rapid HIV results at publicly funded counseling and testing sites is described. Methods: Initial fingerstick testing by either OraQuick or OraQuick Advance was confirmed with Vironostika HIV-1 (BioMerieux) enzyme immunoassay (EIA) and HIV-1 Western blot (Biorad). Discordant results (Oraquick positive/Western blot negative) were followed by repeat Oraquick screening at 4-6 weeks, confirmation of the original EIA and Western blot results, collection of additional serum for hepatitis A (HAV), hepatitis B (HBV), hepatitis C (HCV), HIV by standard enzyme immunoassay, Epstein-Barr virus (EBV), and Rheumatoid factor (RF); collection of additional plasma for ultrasensitive, quantitative RNA determination of HIV. Demographic data were collected using the standard CDC form. Results: Rapid testing began at a single New Jersey site on 11/1/03. Through 10/5/05, 125 sites were conducting rapid testing with 32,463 tests completed. Twenty (0.06%) patients were discordant with a preliminary positive Oraquick rapid test and a negative Western blot. Two patients refused follow-up testing. Three other patients were lost to follow-up. Nine of 10 patients tested were Oraquick positive upon re-examination 4-6 weeks later, but continued to test HIV negative by traditional EIA and Western blot. Other testing included: 12 of 12 tested were negative by ultrasensitive RNA analysis. Eight of 12 (67%) were HAV polyvalent antibody positive, 1 of 12 (8%) had acute HBV, 2 of 9 (22%) had HCV infection, 1 of 12 (8%) had RF, 12 of 12 (100%) had evidence of a distant EBV infection. No instances of an evolving HIV infection were identified. Conclusion: Rapid testing is a reliable, reproducible screening test in publicly funded counseling and testing sites. The 0.06% observed false positive rate in sites with a rigorous QA program is acceptable. Background – Discordant HIV Result DEFINITION: A reactive OraQuick® rapid HIV test followed by a negative or indeterminate Western blot (WB) or immunofluorescent assay (IFA) result. TWO TYPES OF DISCORDANTS TYPE I Positive Oraquick ®, NEGATIVE Western Blot No bands present Client is considered HIV negative and not likely to be in an HIV window. TYPE II Positive Oraquick ®, INDETERMINATE Western Blot Some bands not meeting the criteria to be declared positive are present Possibility the client is in the process of seroconverting. What Causes Discordants? An evolving infection – HIV screen is positive prior to traditional EIA or Western Blot Cross-reacting non-specific antibodies Over-reading by testing personnel TOTAL TESTS 11/1/03 – 10/5/05HIV PRELIM POSITIVEWESTERN BLOT – Discordant 32, (1.7 %)20 (3.6 % of Prelim Pos. – 0.06% Overall) NegativeDiscordantWB Pos 554 PRELIM POS 20 DISCORDANT 15,570 NEGATIVE NJ 2004 RAPID HIV TESTING NegativeDiscordantWB Pos PRELIM POS 32,463 NEGATIVE NJ RAPID HIV TESTING Frequency of Discordants – NJ (2003-5) Rapid Testing in New Jersey – NJ HIV METHODS: The NJ Rapid HIV Program is a large, centralized QA effort (Fig. 1) After an initial positive Oraquick result and negative confirmationoccurs at any site NJ HIV technical support is contacted ( At 4-6 WEEKS: –Repeat HIV by Oraquick –Venipuncture. Collect SST, white top, & purple top tube. Centrifuge and prepare ASAP (< 4 hrs). –Ship to reference laboratory (ARUP) Repeat HIV1/2 EIAQualitative HIV PCR HIV1 Western blot Ultrasenstive Quantitative RNA PCR HAV (Polyvalent)Hepatitis B surf. Ag, Ab, HBcAb HCV AbEBV, RF, –4-6 weeks Independent confirmation of the original negative Western blot, Demographic data were collected using the standard Centers for Disease Control and Prevention counseling and testing form CONCLUSIONS: Between , 20 discordant rapid HIV tests were identified (Fig. 2). A discordant occurs when a + Rapid HIV test fails to confirm by confirmatory Western blot. While evidence of distant EBV and HAV infection exist in more than half of individuals with discordant HIV results, the frequency is similar to that in the US population (Fig. 3) With the growth of NJ statewide program, additional discordant results have been identified. Through September 2006, 58 additional discordants have been identified. Of these, 78% were associated with oral specimens, while 20% were associated with fingerstick specimens. A slightly lower degree of specificity is reported by the manufacturer when using oral specimen types and is apparent in NJ. The possibility of seasonal variation is suggested by monthly data, but remains within the manufacturer’s specificity claims. With the exception of a single NJ case, discordant results in 2006 have not been associated with an evolving infection as demonstrated by > 1 month follow-up utilizing qualitative DNA and quantitative RNA HIV testing, as well as HIV1/2 EIA testing. Specimen Type Correlations with Disease States – NJ (2003-5) Figure 1 Figure 2 Figure 3 NEW JERSEY DISCORDANTS Month to Month Figure 4 Outcome Figure 5 Figure 6